$38.500
+1.559 (+4.05%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de GMAB por análisis de gráficos similares
Alphio's GMAB stock price prediction model matches the current Genmab A/S tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $38.27 (-0.61%). The 1-week path is $38.62 (+0.30%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Genmab A/S?
Genmab A/S (GMAB) is a good buy right now due to its current price of $37, which is significantly below the average analyst price target of $50, indicating a potential upside of 35%. Additionally, the company has demonstrated strong financial performance with a gross margin of 92.73% in Q2 2026, showcasing its efficiency and profitability. However, the main risk is the recent failure of the Epcoritamab trial, which could impact future sales expectations and market acceptance.
GMAB cerró en $38.50 el Monday, tras subir +4.05%
Genmab A/S (GMAB) last closed at $38.5, gaining +4.05%. These facts feed the 1-day and 1-week GMAB price prediction above.
Factores de la previsión
Los factores de la previsión de Genmab A/S (GMAB) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bullish
SMA 200
Bullish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de GMAB, ordenadas por similitud.
Análisis de estacionalidad de GMAB
Historically the probability of a positive October return for GMAB is 61.67%. September offers the highest probability of a positive month at 67.74%, while April is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Proyecciones de precio a 10 años de GMAB
| Mes | Precio mínimo | Precio medio | Precio máximo | ROI potencial |
|---|---|---|---|---|
| Oct 2026 | $17.30 | $21.62 | $22.57 | -43.84% |
| Nov 2026 | $28.07 | $28.69 | $33.47 | -25.48% |
| Dec 2026 | $24.17 | $24.45 | $26.55 | -36.50% |
En 2026, se proyecta que Genmab A/S (GMAB) oscile entre $17.30 y $33.47.
Previsión mensual de Genmab A/S para 2026
En Oct de 2026, se proyecta que Genmab A/S promedie $21.62, con un mínimo de $17.30 y un máximo de $22.57.
En Nov de 2026, se proyecta que Genmab A/S promedie $28.69, con un mínimo de $28.07 y un máximo de $33.47.
En Dec de 2026, se proyecta que Genmab A/S promedie $24.45, con un mínimo de $24.17 y un máximo de $26.55.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.